BRITISH JOURNAL OF HAEMATOLOGY

Volume 116, Issue 1, January 2002

IMAGES IN HAEMATOLOGY

1 **Blood and blisters: porphyria cutanea tarda in myelodysplastic syndrome**
M. Sivakumaran and P. Hudson
2 **Polyclonal hypergammaglobulinaemia with hyperviscosity syndrome**
F. Amati, G. Canellini and P. Beris

HISTORICAL REVIEW

3 **The Langerhans cell histiocytosis X files revealed**
A. Coppes-Zantinga and R. M. Egeler

REVIEWS

10 **Chronic neutrophilic leukaemia: a distinct clinical entity?**
J. T. Reilly
19 **Signalling scaffolds and adaptors in T-cell immunity**
L. Geng and C. E. Rudd
28 **Haematopoietic growth factors in children with neutropenia**
T. Lehrnbecher and K. Welte
57 **Cellular signalling pathways: new targets in leukaemia therapy**
F. Ravandi, M. Talpaz, H. Kantarjian and Z. Estrov

HAEMATOLOGICAL MALIGNANCY

78 **Generation of cytokine-induced killer cells from leukaemic samples with *in vitro* cytotoxicity against autologous and allogeneic leukaemic blasts**
Y. C. Linn, L. C. Lau and K. M. Hui
87 **The *TEL-AML1* real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia**
V. de Haas, W. B. Breunis, R. Dee, O. J. H. Verhagen, W. Kroes, E. R. van Wering, J. J. M. van Dongen, H. van den Berg and C. E. van der Schoot
94 **Matrix metalloproteinase-9 and vascular endothelial growth factor: a possible link in adult T-cell leukaemia cell invasion**
T. Hayashibara, Y. Yamada, Y. Onimaru, C. Tsutsumi, S. Nakayama, N. Mori, T. Miyanishi, S. Kamihira, M. Tomonaga and T. Maita
103 **Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study**
K. Usuki, A. Urabe, T. Masaoka, R. Ohno, H. Mizoguchi, N. Hamajima, T. Miyazaki, Y. Niitsu, Y. Yoshida, A. Miura, A. Shibata, T. Abe, Y. Miura, Y. Ikeda, T. Nomura, T. Nagao, H. Saitou, S. Shirakawa, M. Ohkuma, T. Matsuda, T. Nakamura, A. Horiuchi,

A. Kuramoto, I. Kimura, S. Irino, Y. Niho, K. Takatsuki, M. Tomonaga, H. Uchino, F. Takaku and the Gran AML Study Group

113 **Primary effusion lymphomas exhibit complex and recurrent cytogenetic abnormalities**
K. S. Wilson, R. W. McKenna, S. H. Kroft, D. B. Dawson, Q. Ansari and N. R. Schneider

122 **T-cel. analysis in identical twins reveals an impaired anti-follicular lymphoma immune response in the patient but not in the healthy twin**
E. Gitelson, D. Spaner, R. Buckstein, E. Franssen, K. Hewitt, M. S. Lim, N. Pennell, J. L. Schultze and N. L. Berinstein

128 **Establishment and characterization of a Kaposi's sarcoma-associated herpesvirus- and Epstein–Barr virus-negative malignant lymphoma cell line (OHK) with primary effusion lymphoma immunophenotype**
H. Kuwabara, M. Nagai, K. Kawakami, M. Ohmori, T. Tasaka, Y. Funamoto, G. Yamaoka, H. Nishio, K. Suzuki and H. Mori

135 **Immunochemical studies of antigenic lymphoma-associated proteins**
K. Pulford, H. Roberton, A. H. Banham, C. S. R. Hatton and D. Y. Mason

142 **CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia**
P. Chevallier, D. Penther, H. Avet-Loiseau, N. Robillard, N. Ifrah, B. Mahé, M. Hamidou, H. Maisonneuve, P. Moreau, H. Jardel, J. L. Harousseau, R. Bataille and R. Garand

Short reports

151 **Evolution of myelodysplastic syndrome and acute myelogenous leukaemia in children with hepatitis-associated aplastic anaemia**
A. Ohara, S. Kojima, J. Okamura, H. Inada, H. Kigasawa, S. Hibi and I. Tsukimoto for the Aplastic Anaemia Committee of the Japanese Society of Pediatric Haematology

155 **Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide**
E. Voskaridou, E. Terpos, V. Komninaka, E. Eftyhiadis, M. Mantzourani and D. Loukopoulos

158 **High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphoma**
K. Kuramoto, A. Sakai, K. Shigemasa, Y. Takimoto, H. Asaoku, T. Tsujimoto, K. Oda, A. Kimura, T. Uesaka, H. Watanabe and O. Katoh

162 **Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia**
S. B. Marley, R. John Davidson, J. M. Goldman and M. Y. Gordon

166 **Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma**
C.-A. Liao, C.-M. Lee, H.-C. Wu, M.-C. Wang, S.-N. Lu and H.-L. Eng

170 **t(7;11)(p15;p15) chronic myeloid leukaemia developed into blastic transformation showing a novel *NUP98/HOXA11* fusion**
A. Suzuki, Y. Ito, G. Sashida, S. Honda, T. Katagiri, T. Fujino, T. Nakamura and K. Ohyashiki

PLATELETS, HAEMOSTASIS AND THROMBOSIS

173 **Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis**
B. E. van Aken, P. H. Reitsma and F. R. Rosendaal

178 **Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin**
M. A. Crowther, L. R. Berry, P. T. Monagle and A. K. C. Chan

187 **Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay**
A. F. Riddell, P. V. Jenkins, I. C. Nitu-Whalley, A. H. McCraw, C. A. Lee and S. A. Brown

TRANSPLANTATION

193 **Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukaemia**
A. Pigneux, M. L. Tanguy, M. Michallet, J. P. Jouet, M. Kuentz, J. P. Vernant, N. Milpied, N. Ifrah, J. Y. Cahn, N. Gratecos, O. Reman, H. Cure, D. Caillot, F. Witz, C. Pillier-Loriette, P. Tron and J. Reiffers for the Société Française de Greffe de Moelle (SFGM)

202 **Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma**
A. M. Barbui, M. Galli, G. Dotti, N. Belli, G. Borleri, G. Gritti, P. Bellavita, P. Viera, B. Comotti, T. Barbui and A. Rambaldi

211 **Predicting long-term (≥ 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants**
G. Tricot, T. Spencer, J. Sawyer, D. Spoon, R. Desikan, A. Fassas, A. Badros, M. Zangari, N. Munshi, E. Anaissie, A. Toor and B. Barlogie

218 ***In vitro* expansion of cord blood does not prevent engraftment of severe combined immunodeficient repopulating cells**
P. A. Denning-Kendall, R. Evely, S. Singha, M. Chapman, B. A. Bradley and J. M. Hows

229 **A sequence of immuno-chemotherapy with Rituximab, mobilization of *in vivo* purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma**
M. Lazzarino, L. Arcaini, P. Bernasconi, E. P. Alessandrino, L. Gargantini, R. Cairoli, E. Orlandi, C. Astori, E. Brusamolino, G. Pagnucco, A. A. Colombo, S. Calatroni, I. Iacona, M. B. Regazzi and E. Morra

CORRESPONDENCE

236 **Homozygous factor V leiden mutation in sickle cell anaemia**
U. Kordes, G. Janka-Schaub, A. Kulozik and R. Schneppenheim

237 **The use of oral vitamin K for reversal of over-warfarinization**
H. G. Watson, T. P. Baglin and M. Makris

237 **Allogeneic marrow grafts from unrelated donors with congenital pericentric inversion of chromosome 9**
Y.-K. Keung, M. Pettenati, D. D. Hurd, B. L. Powell and D. H. Buss

239 **ANNOUNCEMENTS**

Volume 116. Issue 2. February 2002

IMAGES IN HAEMATOLOGY

241 **Blastic natural killer cell leukaemia/lymphoma**
N. Chen, S. Agosti and D. Doll

242 **Demonstration of left iliofemoral deep vein thrombosis by magnetic resonance direct thrombus imaging**
J. Kelly, B. J. Hunt and A. Moody

REVIEWS

243 **The optimal management of polycythaemia vera**
J. L. Spivak

255 **Medication errors: causes, prevention and reduction**
J. Allard, J. Carthey, J. Cope, M. Pitt and S. Woodward

HAEMATOLOGICAL MALIGNANCY

266 **ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype**
A. J. Alessandri, G. S. D. Reid, S. A. Bader, B. G. Massing, P. H. B. Sorensen and K. R. Schultz

273 **Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma**
I. M. S. Dahl, T. Rasmussen, G. Kauric and A. Husebekk

278 **Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity**
S. Yaccoby, R. N. Pearse, C. L. Johnson, B. Barlogie, Y. Choi and J. Epstein

291 **Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization**
J. E. Allen, R. E. Hough, J. R. Goepel, S. Bottomley, G. A. Wilson, H. E. Alcock, M. Baird, P. C. Lorigan, E. A. Vandenberghe, B. W. Hancock and D. W. Hammond

299 **Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission**
G. F. Torelli, A. Guarini, G. Palmieri, M. Breccia, A. Vitale, A. Santoni and R. Foa

308 **Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I–II study**
A. Fassas, R. Buffels, A. Anagnostopoulos, E. Gacos, C. Vadikolia, P. Haloudis and P. Kaloyannidis

316 **Cytoprotective antioxidant activity of serum albumin and autocrine catalase in chronic lymphocytic leukaemia**
E. C. Moran, A. S. Kamiguti, J. C. Cawley and A. R. Pettitt

Short reports

329 **Clonally unrelated Hodgkin's disease following autologous stem cell transplant for B-cell lymphoma**
F. Fend, A. Martinez, L. Quintanilla-Martinez, L. Sanz, N. Combalia, M. Raffeld, E. S. Jaffe, E. Montserrat and E. Campo

334 **Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes**
R. Stasi and S. Amadori

338 **Secondary acute myeloid leukaemia with monosomy 7 in identical adult twins**
G. Seipelt, U. Germing, S. Koschmieder, A. Böhme, C. Aul and D. Hoelzer

341 **Spontaneous clinical regression in chronic lymphocytic leukaemia**
R. Thomas, I. Ribeiro, P. Shepherd, P. Johnson, M. Cook, A. Lakhani, R. Kaczmarski, P. Carrington and D. Catovsky

346 **Perforin defects of primary haemophagocytic lymphohistiocytosis in Japan**
N. Suga, H. Takada, A. Nomura, S. Ohga, E. Ishii, K. Ihara, K. Ohshima and T. Hara

PLATELETS, HAEMOSTASIS AND THROMBOSIS

350 **Genotype at the *Secretor* blood group locus is a determinant of plasma von Willebrand factor level**
J. O'Donnell, F. E. Boulton, R. A. Manning and M. A. Laffan

357 **Rapid recovery of platelet count following administration of liposome-encapsulated clodronate in a mouse model of immune thrombocytopenia**
F. Alves-Rosa, C. Stanganelli, J. Cabrera, D. Cymberknop, C. Rubel, S. Vanzulli, N. van Rooijen, M. Palermo and M. A. Isturiz

367 **Absence of mutations in the *HoxA10*, *HoxA11* and *HoxD11* nucleotide coding sequences in thrombocytopenia with absent radius syndrome**
R. A. Fleischman, R. Letestu, X. Mi, D. Stevens, J. Winters, N. Debili and W. Vainchenker

376 **Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women**
A. P. Reiner, M. B. Frank, S. M. Schwartz, M. L. Linenberger, W. T. Longstreth, Jr, G. Teramura, F. R. Rosendaal, B. M. Psaty and D. S. Siscovick

383 **Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort**
V. Gaboulaud, A. Parquet, C. Tahiri, S. Claeyssens, V. Potard, A. Faradji, J. Peynet and D. Costagliola for the Suivi Thérapeutique National des Hémophiles Group

Short report 390 **Axillary vein thrombosis in a healthy donor following platelet apheresis**
D. A. Jones, E. Williams, S. A. Riley and M. Makris

HAEMOPOIESIS

392 **Fetal haemopoietic cells display enhanced migration across endothelium**
K. L. Yong, A. Fahey, G. Pahal, D. C. Linch, A. Pizzey, N. S. B. Thomas, E. Jauniaux, C. Kinnon and A. J. Thrasher

401 **Expression of the *Ly-6A* (Sca-1) *lacZ* transgene in mouse haematopoietic stem cells and embryos**
X. Ma, M. de Bruijn, C. Robin, M. Peeters, J. Kong-A-San, T. de Wit, C. Snoijs and E. Dzierzak

409 **Very low frequencies of human normal CD34$^+$ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells**
N. Hosen, Y. Sonoda, Y. Oji, T. Kimura, H. Minamiguchi, H. Tamaki, M. Kawakami, M. Asada, K. Kanato, M. Motomura, M. Murakami, T. Fujioka, T. Masuda, E. H. Kim, A. Tsuboi, Y. Oka, T. Soma, H. Ogawa and H. Sugiyama

421 **p53-mediated downregulation of Chk1 abrogates the DNA damage-induced G2M checkpoint in K562 cells, resulting in increased apoptosis**
M. Cummings, T. Siitonen, K. Higginbottom, A. C. Newland and P. D. Allen

429 **Expression of transcription factors Pu.1, Spi-B, Blimp-1, BSAP and oct-2 in normal human plasma cells and in multiple myeloma cells**
M. Nagy, B. Chapuis and T. Matthes

RED CELLS

436 **Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease**
M. T. Gladwin, J. H. Shelhamer, F. P. Ognibene, M. E. Pease-Fye, J. S. Nichols, B. Link, D. B. Patel, M. A. Jankowski, L. K. Pannell, A. N. Schechter and G. P. Rodgers

445 **Novel alleles at the JK blood group locus explain the absence of the erythrocyte urea transporter in European families**
N. M. Irshaid, N. I. Eicher, H. Hustinx, J. Poole and M. L. Olsson

454 **A novel rearrangement of the human fetal globin genes leading to a six γ-globin gene haplotype**
I. Gonçalves, j. Lavinha, R. Ducrocq and L. Osório-Almeida

458 **Iron deficiency can upregulate expression of transferrin receptor at both the mRNA and protein level**
X. Tong, H. Kawabata and H. P. Koeffler

Short report 465 **Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus**
S. Perrotta, F. Locatelli, A. La Manna, L. Cennamo, P. De Stefano and B. Nobili

TRANSPLANTATION

468 **Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF**
T. Demirer, M. Ayli, M. Ozcan, N. Gunel, R. Haznedar, M. Dagli, T. Fen, Y. Genc, S. Dincer, O. Arslan, G. Gürman, S. Demirer, G. Ozet, A. Uysal, N. Konuk, O. Ilhan, H. Koc and H. Akan

475 **Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients**
R. Martino, M. Subirá, M. Rovira, C. Solano, L. Vázquez, G. F. Sanz, A. Urbano-Ispizua, S. Brunet and R. De la Cámara for the alloPBSCT and Infectious/Non-infectious Complications Subcommittees of the Grupo Español de Trasplante Hematopoyético (GETH)

483 **Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants**
F. A. Al-Kasim, I. Thornley, M. Rolland, W. Lau, R. Tsang, M. H. Freedman, E. F. Saunders, S. Calderwood and J. J. Doyle

491 **Long-term follow-up of recipients of allogeneic bone marrow grafts reveals no progressive telomere shortening and provides no evidence for haematopoietic stem cell exhaustion**
E. S. D. de Pauw, S. A. Otto, J. T. Wijnen, J. M. Vossen, M. H. van Weel, H. J. Tanke, F. Miedema, R. Willemze, H. Roelofs and W. E. Fibbe

Short report 497 **Non-myeloablative bone marrow transplantation in an adult with Wiskott–Aldrich syndrome**
H. J. Longhurst, D. Taussig, T. Haque, D. Syndercombe-Court, J. Cavenagh, J. D. Edgar and M. R. Helbert

CORRESPONDENCE

500 **Type of postgrafting immunosuppression after nonmyeloablative blood cell transplantation may influence risk of delayed haemolysis due to minor ABO incompatibility**
M. Mielcarek, J. M. Zaucha, B. Sandmaier, D. Maloney, J. Butrynski, M. Maris, L. Feinstein, B. Torok-Storb and R. Storb
502 **ANNOUNCEMENTS**

Volume 116, Issue 3, March-I 2002

IMAGES IN HAEMATOLOGY

503 ***Histoplasma capsulatum* in peripheral blood smears**
G. A. Kennedy, J. L. Curnow, J. Gooch, B. Williams, P. Wood, C. Pitman, E. McBryde and M. Woods
504 **A case of compound heterozygosity for Hb S and Hb S Oman**
R. Al Jahdhamy, H. Makki, G. Farrell and S. Al Azzawi

REVIEWS

505 **Cytoprotective function of keratinocyte growth factor in tumour therapy-induced tissue damage**
K. Wirth and R. Mertelsmann
511 **Prospects for anti-Ras drugs**
M. R. Ahmadian

HAEMATOLOGICAL MALIGNANCY

519 **P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in *de novo* adult acute lymphoblastic leukaemia**
D. Damiani, A. Michelutti, M. Michieli, P. Masolini, R. Stocchi, A. Geromin, A. Ermacora, D. Russo, R. Fanin and M. Baccarani
528 **Cytotoxicity of 2-chlorodeoxyadenosine and arabinosylcytosine in leukaemic lymphoblasts from paediatric patients: significance of cellular nucleoside transporter content**
A. M. P. Wright, A. R. P. Paterson, B. Sowa, J. J. Akabutu, P. E. Grundy and W. P. Gati
538 **Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients**
K. Karlsson, M. Strömberg, J. Liliemark, A. Delannoy, S. A. N. Johnson, A. Porwit, E. Kimby, G. Lärfars, I. Cristiansen, G. Nilsson, F. Celsing, G. Sundström, M. Luthman, U. Tidefelt, J. Wallvik and G. Juliusson

549 **Surface immunoglobulin on B lymphocytes as a potential target for specific peptide ligands in chronic lymphocytic leukaemia**
L. Buhl, P. B. Szecsi, G. G. Gisselø and C. Schafer-Nielsen

555 **Dual effects of arsenic trioxide (As_2O_3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation**
M. T. Rojewski, C. Baldus, W. Knauf, E. Thiel and H. Schrezenmeier

564 **Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes**
P. L. Reddy, V. T. Shetty, D. Dutt, A. York, S. Dar, S. D. Mundle, K. Allampallam, S. Alvi, N. Galili, G. S. Saberwal, S. Anthwal, M. Shaikh, S. Suleman, S. Y. Kamal and A. Raza

576 **Melphalan treatment in patients with myelofibrosis with myeloid metaplasia**
M. C. Petti, R. Latagliata, T. Spadea, A. Spadea, E. Montefusco, M. A. Aloe Spiriti, G. Avvisati, M. Breccia, E. Pescarmona and F. Mandelli

582 **Hypermethylation of the $P15^{INK4b}$ and $P16^{INK4a}$ in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation**
J. C. Wang, W. Chen, S. Nallusamy, C. Chen and A. D. Novetsky

587 **Genetic polymorphisms in microsomal epoxide hydrolase and susceptibility to adult acute myeloid leukaemia with defined cytogenetic abnormalities**
L. Lebailly, E. V. Willett, A. V. Moorman, E. Roman, R. Cartwright, G. J. Morgan and C. P. Wild

Short reports

595 **Severe decrease in peripheral blood dendritic cells in hairy cell leukaemia**
A. Bourguin-Plonquet, H. Rouard, F. Roudot-Thoraval, C. Bellanger, J. Marquet, M.-H. Delfau-Larue, M. Diviné and J.-P. Farcet

598 **Chromosomal abnormalities in T-cell large granular lymphocyte leukaemia: report of two cases and review of the literature**
K. F. Wong, J. C. W. Chan, H. S. Y. Liu, C. Man and Y. L. Kwong

601 **Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes**
T. Azuma, M. Makita, K. Ninomiya, S. Fujita, M. Harada and M. Yasukawa

PLATELETS, HAEMOSTASIS AND THROMBOSIS

604 **A novel immunocytochemical assay for the detection of serotonin in platelets**
E. Maurer-Spurej, K. Dyker, W. A. Gahl and D. V. Devine

612 **Elevation of serum thrombopoietin precedes thrombocytosis in acute infections**
A. Ishiguro, Y. Suzuki, M. Mito, T. Shimbo, K. Matsubara, T. Kato and H. Miyazaki

619 **Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients**
F. E. Preston, S. T. Laidlaw, B. Sampson and S. Kitchen

625 **The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders**
J. R. Meinardi, S. Middeldorp, P. J. de Kam, M. M. W. Koopman, E. C. M. van Pampus, K. Hamulyák, M. H. Prins, H. R. Büller and J. van der Meer

632 **Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors**
N. O'Connell, C. Mc Mahon, J. Smith, K. Khair, I. Hann, R. Liesner and O. P. Smith

636 **Activation of recombinant αIIbβ3 expressed in Chinese hamster ovary cells exposes different binding sites for fibrinogen or von Willebrand factor: evidence using monoclonal antibodies to αIIbβ3**
M. Mekrache, N. Kieffer and D. Baruch

Short reports

645 **Massive pseudotumour resection with recombinant factor VIIa (NovoSeven) cover**
N. O'Connell, J. Chen, M. Byrne, E. O'Shea, H. Smyth and O. P. Smith

649 **The pharmacodynamics of tinzaparin in healthy volunteers**
J.-P. Cambus, S. Saivin, J.-J. Heilmann, H. Caplian, B. Boneu and G. Houin

653 **Long-haul flights and deep vein thrombosis: a significant risk only when additional factors are also present**
R. Arya, J. A. Barnes, U. Hossain, R. K. Patel and A. T. Cohen

LEUCOCYTES

655 **Cellular copper content modulates differentiation and self-renewal in cultures of cord blood-derived CD34$^+$ cells**
T. Peled, E. Landau, E. Prus, A. J. Treves and E. Fibach

Short report

662 **Persistent polyclonal B lymphocytosis: an expansion of cells showing IgVH gene mutations and phenotypic features of normal lymphocytes from the CD27$^+$ marginal zone B-cell compartment**
I. Salcedo, A. Campos-Caro, A. Sampalo, E. Reales and J. A. Brieva

RED CELLS

667 **A novel deletion of the L-ferritin iron-responsive element responsible for severe hereditary hyperferritinaemia–cataract syndrome**
M. Cazzola, B. Foglieni, G. Bergamaschi, S. Levi, M. Lazzarino and P. Arosio

Short report

671 **G6PD gene mutations in India producing drug-induced haemolytic anaemia**
S. Sukumar, R. Colah and D. Mohanty

TRANSFUSION

673 **Transfusion-related acute lung injury caused by human leucocyte antigen class II antibody**
B. Flesch and J. Neppert

677 **Platelet αIIbβ3 recombinant autoantibodies from the B-cell repertoire of a post-transfusion purpura patient**
N. A. Watkins, P. A. Smethurst, D. Allen, G. A. Smith and W. H. Ouwehand

TRANSPLANTATION

686 **Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation**
J. Sánchez, J. Serrano, P. Gómez, F. Martínez, C. Martín, L. Madero, C. Herrera, J. M. García, J. Casaño and A. Torres

695 **The CD19$^+$ B-cell counts at peripheral blood stem cell mobilization determine different levels of tumour contamination and autograft purgability in low-grade lymphoma**
C. Straka, F. Oduncu, E. Drexler, M. Mitterer, B. Schnabel, A. König, N. Brack, C. Nerl and B. Emmerich

702 **Interleukin 10, produced in abundance by human newborn T cells, may be the regulator of increased tolerance associated with cord blood stem cell transplantation**
E. Rainsford and D. J. Reen

710 **Epstein–Barr virus-specific T-cell cytotoxicity is mediated through the perforin pathway in patients with lymphoproliferative disorders after allogeneic bone marrow transplantation**
A. Yoshimi, I. Tsuge, H. Namizaki, Y. Hoshino, H. Kimura, Y. Takahashi, N. Watanabe, K. Kuzushima and S. Kojima

716 **Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia**
F. O. Smith, R. King, G. Nelson, J. E. Wagner, K. A. Robertson, J. E. Sanders, N. Bunin, P. D. Emanuel and S. M. Davies for the National Marrow Donor Program

CORRESPONDENCE

725 **Flow cytometry and the study of cerebrospinal fluid in leukaemic patients: additional facts**
P. F. Abellán, M. Luz de la Sen, B. Sánchez, C. Rivas and R. Calatayud

726 **Reversible abnormal chromatin clumping in granulocytes from six transplant patients treated with mycophenolate mofetil: a rare adverse effect mimicking abnormal chromatin clumping syndrome**
S. Daliphard, F. Accard, C. Delattre, O. Toupance, C. Guyot, F. Méchinaud, A. Chassaing, M. Hourmant, P. Rousset and G. Potron

727 **Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment**
H. W. Auner, A. Wölfler, C. Beham-Schmid, D. Strunk, W. Linkesch and H. Sill

729 **BOOK REVIEW**

730 **ERRATUM**

Volume 116, Issue 4, March-II 2002

IMAGES IN HAEMATOLOGY

731 **Stomatocytic elliptocytosis and 'neutrophil drumsticks' as a marker of stem cell engraftment**
F. S-Abdul-Wahid and C. Soon-Keng

732 **Renal Hodgkin's disease**
C. Pilatrino, A. Cataldi, A. Guerrasio and G. Saglio

REVIEWS

733 **Sideroblastic anaemias**
T. Alcindor and K. R. Bridges

744 **Class III receptor tyrosine kinases: role in leukaemogenesis**
J. T. Reilly

HAEMATOLOGICAL MALIGNANCY

758 **A highly specific and sensitive fluorescence *in situ* hybridization assay for the detection of t(4;11)(q21;q23) and concurrent submicroscopic deletions in acute leukaemias**
M. König, M. Reichel, R. Marschalek, O. A. Haas and S. Strehl

765 **Expression of the signal transduction molecule ζ in peripheral and tumour-associated lymphocytes in Hodgkin's disease in relation to the Epstein–Barr virus status of the tumour cells**
J. Sjöberg, M. Andersson, C. Garcia, K. A. Palucka, M. Björkholm, A. Porwit-MacDonald and P. Pisa

774 **Multidrug resistance mechanisms in chronic lymphocytic leukaemia**
U. Consoli, A. Santonocito, F. Stagno, P. Fiumara, A. Privitera, G. Parisi, G. M. Giustolisi, B. Pavone, G. A. Palumbo, F. Di Raimondo, G. Milone, P. Guglielmo and R. Giustolisi

781 **High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma**
G. P. Summerfield, P. R. A. Taylor, P. J. Mounter and S. J. Proctor

787 **Interleukin 10 abolishes the growth inhibitory effects of all-*trans* retinoic acid on human myeloma cells**
T. Otsuki, K. Yata, H. Sakaguchi, J. Kurebayashi, Y. Matsuo, M. Uno, T. Fujii, S. Eda, Y. Isozaki, Y. Yawata, O. Yamada, H. Wada, T. Sugihara and A. Ueki

796 **Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma**
T. Iwasaki, T. Hamano, A. Ogata, N. Hashimoto, M. Kitano and E. Kakishita

803 **Clinical evaluation of a polymerase chain reaction assay to detect *Aspergillus* species in bronchoalveolar lavage samples of neutropenic patients**
D. Buchheidt, C. Baust, H. Skladny, M. Baldus, S. Bräuninger and R. Hehlmann

812 **Typical essential thrombocythaemia does not express bcr–abelson fusion transcript**
G. Damaj, E. Delabesse, C. Le Bihan, V. Asnafi, M. Rachid, F. Lefrère, I. Radford-Weiss, E. Macintyre, O. Hermine and B. Varet

817 **Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cisternae in bone marrow biopsies of myelodysplastic syndrome patients**
V. Shetty, S. Hussaini, S. Alvi, L. Joshi, A. Shaher, B. Dangerfield, F. Nascimben, S. Mundle, K. Allampallam, P. Reddy, N. Galili and A. Raza

826 **Outbreak of vancomycin-resistant *Enterococcus faecium* in a haematology unit: risk factor assessment and successful control of the epidemic**
G. J. Timmers, W. C. van der Zwet, I. M. Simoons-Smit, P. H. M. Savelkoul, H. H. M. Meester, C. M. J. Vandenbroucke-Grauls and P. C. Huijgens

Short report 834 **High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival**
B. Laupeze, L. Amiot, B. Drenou, M. Bernard, B. Branger, J. M. Grosset, T. Lamy, R. Fauchet and O. Fardel

PLATELETS, HAEMOSTASIS AND THROMBOSIS

839 **Genotyping of human platelet antigen-1 by gene amplification and labelling in one system and automated fluorescence correlation spectroscopy**
S. Weber, S. A. Hummel, A.-A. Weber, R. F. Zirwes, O. H. Weiner and B. E. Reuber

844 **European Concerted Action on Anticoagulation (ECAA): multicentre international sensitivity index calibration of two types of point-of-care prothrombin time monitor systems**
L. Poller, M. Keown, N. Chauhan, A. M. H. P. van den Besselaar, A. Tripodi, J. Jespersen, C. Shiach, M. H. Horellou, D. Dias, N. Egberg, J. A. Iriarte, I. Kontopoulou-Griva and B. Otridge

851 **Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis**
F. R. Rosendaal, M. Vessey, A. Rumley, E. Daly, M. Woodward, F. M. Helmerhorst and G. D. O. Lowe

855 **Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis**
F. Passamonti, L. Malabarba, E. Orlandi, C. Pascutto, E. Brusamolino, C. Astori, C. Baratè, A. Canevari, A. Corso, P. Bernasconi, M. Cazzola and M. Lazzarino

862 **Reduced transforming growth factor-β1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura**
P.-O. Andersson, A. Olsson and H. Wadenvik

868 **Anticoagulant effects of a synthetic peptide containing residues Thr2253–Gln-2270 within factor VIII C2 domain that selectively inhibits factor Xa-catalysed factor VIII activation**
K. Nogami, M. Shima, K. Nishiya, K. Hosokawa, E. L. Saenko, J. C. Giddings, I. Tanaka and A. Yoshioka

875 **True anti-anionic phospholipid IgM antibodies can exert lupus anticoagulant activity**
T. Gallart, C. Benito, J.-C. Reverter, F. Bosch, M. Blay, D. Tàssies, E. Vigorito, R. Cervera, J. Font, R. Gomis, E. Campo and J. Vives

887 **The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays**
P. Eichler, R. Raschke, N. Lubenow, O. Meyer, P. Schwind and A. Greinacher

892 **Effect of nitric oxide modulation on systemic haemodynamics and platelet activation determined by P-selectin expression**
J. L. Ritchie, H. D. Alexander, P. Allen, D. Morgan and G. E. McVeigh

899 **Lack of multimer organization of von Willebrand factor in an acquired von Willebrand syndrome**
A. Casonato, E. Pontara, A. Doria, A. Bertomoro, M. G. Cattini, P. F. Gambari and A. Girolami

Short reports

905 **Plasma exchange (PEX) as a source of protein C for acute onset protein C pathway failure**
A. Hodgson, T. Ryan, J. Moriarty, G. Mellotte, C. Murphy and O. P. Smith

909 **von Willebrand factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura**
M. A. Sahud, S. Claster, L. Liu, M. Ero, K. Harris and M. Furlan

TRANSPLANTATION

912 ***Ex vivo* expansion of megakaryocyte progenitor cells from normal bone marrow and peripheral blood and from patients with haematological malignancies**
A. Blair, C. L. Baker, D. H. Pamphilon and P. A. Judson

Short report

920 **Adoptive therapy with monocyte-derived macrophages in the setting of high dose chemotherapy and peripheral blood stem cell transplantation**
S. W. Krause, M. Gnad, A. Reichle and R. Andreesen

CORRESPONDENCE

923 **Second malignancies in patients with essential thrombocythaemia**
M. L. Randi, F. Fabris and A. Girolami

924 **Veno-occlusive disease after an anti-CD33 therapy (gemtuzumab ozogamicin)**
J. N. Bastie, F. Suzan, I. Garcia, F. Isnard, T. de Revel, C. Terre, D. Mayeur, C. Abraham, R. Lavielle and S. Castaigne

925 ERRATUM

926 AUTHOR AND KEYWORD INDEXES FOR VOLUME 116